Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.67 |
| ▸ | FLT1 | P17948 | 13/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.67 |
| ▸ | EGFR | P00533 | 5/20 | 0.50 |
| ▸ | FLT4 | P35916 | 5/20 | 0.50 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.42 |
| ▸ | ILK | Q13418 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477340 | 0.86 | KDR (0.55) | KDRFLT1FGFR1EGFRFLT4 | |
| Hydrochloric Acid SCHEMBL6517806 | 0.86 | FLT1 (0.50) | KDRFLT1FGFR1EGFRFLT4 | |
| SCHEMBL1888746 | 0.86 | KDR (0.55) | KDRFLT1FGFR1EGFRFLT4 | |
| Hydrochloric Acid SCHEMBL6896031 | 0.83 | KDR (0.52) | KDRFLT1FGFR1EGFRFLT4 | |
| SCHEMBL6519234 | 0.81 | FLT1 (0.55) | KDRFLT1FGFR1EGFRFLT4 | |
| SCHEMBL7864807 | 0.80 | KDR (1.00) | KDRFLT1FGFR1EGFRFLT4 | |
| Hydrochloric Acid SCHEMBL7460915 | 0.80 | KDR (0.49) | KDRFLT1FGFR1EGFRFLT4 | |
| SCHEMBL7738590 | 0.78 | KDR (0.60) | KDRFLT1FGFR1EGFRFLT4 | |
| SCHEMBL7738587 | 0.78 | KDR (0.60) | KDRFLT1FGFR1EGFRFLT4 | |
| SCHEMBL6529811 | 0.78 | HPGD (0.49) | KDRFLT1FGFR1EGFRFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020173646-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA LIMITED | 2002-11-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173646-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | CNKSR1, FLT1, VEGFA | KDR 4/4885FLT1 2/4885FGFR1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.